{平台标识} {固定描述} Leerink has raised its price target on BeOne Medicines (ONC), reflecting an updated analyst assessment of the biopharmaceutical company’s prospects. The adjustment may signal increased confidence in the firm’s pipeline or near-term catalysts, though no specific target price has been disclosed in the available information.
Leerink Revises Price Target on BeOne Medicines: Market Implications for ONC - {财报副标题}
News Analysis
© 2026 Market Analysis. All data is for informational purposes only.